ResMed director Jan De Witte plans $102K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ResMed Inc. (RMD) director Jan De Witte reported a planned sale of 429 common shares, with an approximate sale date of November 17, 2026 and an aggregate market value of $101,673.00. The shares were acquired from the issuer through restricted stock vesting on November 11, 2026, as compensation. The notice lists August 19, 2026 as the plan adoption or instruction date under Rule 10b5-1.
Key Figures
Key Terms
restricted stock vesting financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.